RxDoctor Payments Data

Sarah Hunt

Family · Indianapolis, INNPI 1336122571

Payments from drug & device makers

$1,734in general payments, 2019–2025

Across 54 payments — averaging $32.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$420
  • AstraZeneca$367
  • Novo Nordisk$196
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$152
  • Edwards Lifesciences$136
  • Boston Scientific$111
  • plus $351 from 10 others

What the payments were for

  • Food & beverage$1,734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,734 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$5,945
Medicare patients
56
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan115$116,855
JardianceEmpagliflozin65$67,154
FarxigaDapagliflozin Propanediol51$34,593
EliquisApixaban22$21,470
Torsemide173$2,739
Metoprolol Succinate136$1,321
Potassium Chloride39$1,134
Hydralazine Hcl58$931
Isosorbide Mononitrate ErIsosorbide Mononitrate64$839
Carvedilol130$803
Bumetanide12$801
Spironolactone50$323
Amlodipine Besylate84$318
Furosemide94$316
Klor-Con M20Potassium Chloride18$274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$82$116,855115 claims
Boehringer IngelheimJardiance$43$67,15465 claims
AstraZenecaFarxiga$367$34,59351 claims
PfizerEliquis$72$21,47022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →